Catalyst Wire Dossier Catalyst Wire Dossier

Fluticasone furoate/vilanterol inhalation powder 100/25 mcg

fluticasone furoate/vilanterol · GlaxoSmithKline
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Fluticasone furoate/vilanterol inhalation powder 100/25 mcg, covering 2014-02-06 to 2014-02-06. Get the full timeline:

Most recent: Clinical Trial Update: Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD) [Phase 3]

See pricing